Pubblicazioni

Autori:

Borghesani, Michele; Reni, Anna; Lauricella, Eleonora; Rossi, Alice; Moscarda, Viola; Trevisani, Elena; Torresan, Irene; Al-Toubah, Taymeyah; Filoni, Elisabetta; Luchini, Claudio; De Robertis, Riccardo; Landoni, Luca; Scarpa, Aldo; Porta, Camillo; Milella, Michele; Strosberg, Jonathan; Cives, Mauro; Cingarlini, Sara

Titolo:

Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms

Anno:

2024

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

Elettronico

Referee:

No

Nome rivista:

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

ISSN Rivista:

1540-1405

N° Volume:

22

Numero o Fascicolo:

5

Intervallo pagine:

1-8

Parole chiave:

G3 NETs; high-grade neuroendocrine neoplasm; mFOLFIRINOX; miNEN; neuroendocrine carcinoma

Breve descrizione dei contenuti:

Background: High-grade neuroendocrine neoplasms (NENs) comprise both well-differentiated grade 3 neuroendocrine tumors (G3 NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) nearly always include poorly differentiated NEC as the neuroendocrine component. The efficacy and safety of frontline mFOLFIRINOX chemotherapy has never been investigated in patients with high-grade NENs. Patients and methods: We conducted a multi-institutional retrospective analysis of patients with advanced high-grade NEN of the gastroenteropancreatic tract or of unknown origin seen between February 2016 and April 2023 who received treatment with frontline mFOLFIRINOX. Results: A total of 35 patients were included (G3 NETs: n=2; NECs: n=25; MiNENs: n=8; stage III: n=5; stage IV: n=30). The objective response rate was 77% (complete response: 3%; partial response: 74%). Median progression-free survival was 12 months (95% CI, 9.2-16.2 months) and median overall survival was 20.6 months (95% CI, 17.2-30.6 months). No significant differences in efficacy were seen according to primary site, histopathology, and Ki-67 proliferative index. All 5 patients with stage III disease who received mFOLFIRINOX obtained an objective response and underwent radical surgery or definitive radiotherapy with curative intent, with a recurrence rate of 40%. Grade 3 or 4 adverse events were observed in 43% of patients (mainly neutropenia and diarrhea). Females were at significantly increased risk of developing severe toxicities. Conclusions: mFOLFIRINOX shows antitumor activity against high-grade NENs. Well-designed, prospective clinical trials are needed to assess the efficacy of mFOLFIRINOX in both the neoadjuvant and metastatic settings.

Note:

M. Borghesani and A. Reni are co–first authors. M. Cives and S. Cingarlini are co–last authors. Online Publication Date: 14 May 2024

Id prodotto:

139678

Handle IRIS:

11562/1126586

ultima modifica:

21 agosto 2024

Citazione bibliografica:

Borghesani, Michele; Reni, Anna; Lauricella, Eleonora; Rossi, Alice; Moscarda, Viola; Trevisani, Elena; Torresan, Irene; Al-Toubah, Taymeyah; Filoni, Elisabetta; Luchini, Claudio; De Robertis, Riccardo; Landoni, Luca; Scarpa, Aldo; Porta, Camillo; Milella, Michele; Strosberg, Jonathan; Cives, Mauro; Cingarlini, Sara, Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms «JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK» , vol. 22 , n. 5 , 2024 , pp. 1-8

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo